Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Oct-24 8:06 PM View:  | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 15-Oct-24 | Planned Option Sale | 13,689 | $30.50 | $417,579.00 | (15%) 90.12K to 76.43K | |
| 16-Oct-24 8:06 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 15-Oct-24 | Option Exercise | 14,825 | $0.62 | $9,117.38 | 20% 75.29K to 90.12K | |
| 16-Oct-24 8:06 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 15-Oct-24 | Sale (Planned) | 1,136 | $30.50 | $34,653.40 | (1%) 76.43K to 75.29K | |
| 16-Oct-24 8:06 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 14-Oct-24 | Option Exercise | 5,000 | $0.62 | $3,075.00 | 7% 75.29K to 80.29K | |
| 16-Oct-24 8:06 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 14-Oct-24 | Planned Private Option Sale | 40,000 | $30.15 | $1,206,080.00 | (12%) 326.29K to 286.29K | |
| 16-Oct-24 8:06 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 14-Oct-24 | Planned Option Sale | 6,136 | $30.03 | $184,258.00 | (8%) 80.29K to 74.16K | |
| 16-Oct-24 8:06 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 14-Oct-24 | Option Exercise | 40,000 | $21.09 | $843,600.00 | 14% 286.29K to 326.29K | (7%) |
| 23-Sep-24 6:00 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 20-Sep-24 | Planned Option Sale | 5,500 | $27.65 | $152,086.00 | (7%) 80.79K to 75.29K | |
| 23-Sep-24 6:00 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 20-Sep-24 | Option Exercise | 5,500 | $0.62 | $3,382.50 | 7% 75.29K to 80.79K | |
| 13-Sep-24 5:14 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 10-Sep-24 | Private Sale | 637 | $26.18 | $16,676.70 | (< 1%) 75.93K to 75.29K | |
| 13-Sep-24 5:10 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 10-Sep-24 | Private Sale | 1,738 | $26.18 | $45,500.80 | (< 1%) 607.15K to 605.42K | |
| 13-Sep-24 5:13 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 10-Sep-24 | Private Sale | 639 | $26.18 | $16,729.00 | (2%) 41.79K to 41.15K | |
| 13-Sep-24 5:16 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 10-Sep-24 | Private Sale | 568 | $26.18 | $14,870.20 | (< 1%) 296.85K to 296.29K | |
| 13-Sep-24 5:11 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 10-Sep-24 | Private Sale | 537 | $26.18 | $14,058.70 | (< 1%) 181.24K to 180.71K | |
| 05-Sep-24 4:08 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 03-Sep-24 | Private Sale (Planned) | 5,000 | $26.72 | $133,588.00 | (2%) 301.85K to 296.85K | |
| 05-Sep-24 4:05 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 03-Sep-24 | Option Exercise | 949 | $0.62 | $583.64 | 1% 75.93K to 76.88K | |
| 05-Sep-24 4:05 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 03-Sep-24 | Planned Option Sale | 949 | $27.61 | $26,205.70 | (1%) 76.88K to 75.93K | |
| 29-Aug-24 4:30 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 27-Aug-24 | Planned Option Sale | 23,175 | $26.41 | $612,098.00 | (36%) 64.97K to 41.79K | |
| 29-Aug-24 4:30 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 27-Aug-24 | Option Exercise | 23,175 | $21.09 | $488,761.00 | 55% 41.79K to 64.97K | |
| 29-Aug-24 4:30 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 26-Aug-24 | Option Exercise | 75,159 | $14.57 | $1,095,330.00 | 180% 41.79K to 116.95K | |
| 28-Aug-24 11:11 AM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 26-Aug-24 | Option Exercise | 5,200 | $0.62 | $3,198.00 | 7% 75.93K to 81.13K | |
| 28-Aug-24 11:11 AM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 26-Aug-24 | Planned Option Sale | 5,200 | $27.51 | $143,073.00 | (6%) 81.13K to 75.93K | |
| 29-Aug-24 4:30 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 26-Aug-24 | Planned Option Sale | 75,159 | $27.21 | $2,045,150.00 | (64%) 116.95K to 41.79K | |
| 28-Aug-24 11:11 AM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 23-Aug-24 | Planned Option Sale | 8,851 | $27.53 | $243,641.00 | (10%) 84.78K to 75.93K | |
| 28-Aug-24 11:11 AM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 23-Aug-24 | Option Exercise | 8,851 | $0.62 | $5,443.37 | 12% 75.93K to 84.78K | |
| 20-Aug-24 11:45 AM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 16-Aug-24 | Option Exercise | 24,538 | $0.62 | $15,090.90 | 4% 582.62K to 607.15K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 25-Jul-24 | Option Exercise | 22,272 | $7.01 | $156,104.00 | 53% 41.79K to 64.06K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 25-Jul-24 | Planned Option Sale | 22,272 | $27.61 | $614,820.00 | (35%) 64.06K to 41.79K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 24-Jul-24 | Option Exercise | 139,083 | $7.01 | $974,833.00 | 333% 41.79K to 180.87K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 24-Jul-24 | Planned Option Sale | 139,083 | $26.98 | $3,753,040.00 | (77%) 180.87K to 41.79K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 23-Jul-24 | Option Exercise | 500 | $7.01 | $3,504.50 | 1% 41.79K to 42.29K | |
| 25-Jul-24 5:54 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 23-Jul-24 | Planned Option Sale | 500 | $28.01 | $14,005.00 | (1%) 42.29K to 41.79K | |
| 18-Jul-24 9:41 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 16-Jul-24 | Planned Option Sale | 29,803 | $28.05 | $835,825.00 | (39%) 76.6K to 46.8K | |
| 18-Jul-24 9:41 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 16-Jul-24 | Option Exercise | 29,803 | $7.01 | $208,889.00 | 64% 46.8K to 76.6K | |
| 18-Jul-24 9:41 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 16-Jul-24 | Sale (Planned) | 5,008 | $28.05 | $140,449.00 | (11%) 46.8K to 41.79K | |
| 13-Jun-24 6:09 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 2,831 | $22.64 | $64,093.80 | (6%) 49.63K to 46.8K | |
| 13-Jun-24 6:06 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 2,380 | $22.64 | $53,885.60 | (1%) 182.56K to 180.18K | |
| 13-Jun-24 6:11 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 2,825 | $22.64 | $63,960.80 | (4%) 77.69K to 74.87K | |
| 13-Jun-24 6:01 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 7,894 | $22.64 | $178,728.00 | (1%) 589.45K to 581.55K | |
| 13-Jun-24 6:04 PM View: | Lamy Patrick Senior VP, Commercial Strategy | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 569 | $22.64 | $12,882.70 | (3%) 19.13K to 18.56K | |
| 13-Jun-24 6:13 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 11-Jun-24 | Private Sale | 2,516 | $22.64 | $56,964.80 | (< 1%) 313.31K to 310.79K | |
| 05-Jun-24 5:05 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 03-Jun-24 | Market Sale (Planned) | 5,000 | $19.29 | $96,440.00 | (2%) 318.31K to 313.31K | (2%) |
| 02-May-24 9:07 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 01-May-24 | Market Sale (Planned) | 5,000 | $20.15 | $100,750.00 | (2%) 323.31K to 318.31K | 2% |
| 03-Apr-24 6:55 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 01-Apr-24 | Private Sale (Planned) | 5,000 | $24.38 | $121,913.00 | (< 1%) 592.01K to 587.01K | |
| 15-Mar-24 4:42 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 619 | $28.33 | $17,536.30 | (< 1%) 183.18K to 182.56K | |
| 15-Mar-24 4:45 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 723 | $28.33 | $20,482.60 | (< 1%) 78.42K to 77.69K | |
| 15-Mar-24 4:44 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 724 | $28.33 | $20,510.90 | (1%) 50.35K to 49.63K | |
| 15-Mar-24 4:43 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 1,969 | $28.33 | $55,781.80 | (< 1%) 591.42K to 589.45K | |
| 15-Mar-24 4:42 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 651 | $28.33 | $18,442.80 | (< 1%) 328.96K to 328.31K | |
| 06-Mar-24 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 04-Mar-24 | Planned Option Sale | 75,000 | $32.87 | $2,465,060.00 | (11%) 666.42K to 591.42K |
